Hakim Azfar Ali
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hakim Azfar Ali has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
Katherine Young
Duke Univ Hosp, Div Pulm Allergy & Crit Care, Durham, NC USA
2 shared publicationsOriol Manuel
University Hospital of Lausanne, CHUV
2 shared publicationsScott M. Palmer
Duke University Medical Center
2 shared publications- Alexander D. Stoker
Department of Anesthesiology and Perioperative Medicine, Mayo Clinic in Arizona, Phoenix, Arizona, USA
1 shared publication - Anne Hicks
Department of Anesthesiology, Cardiothoracic Anesthesiology Division, Duke University Medical Center, Durham, NC
1 shared publication - Arya M. Iranmanesh
From the Department of Radiology, Division of Cardiothoracic Imaging (M.R.D., H.P.M., A.M.I., H.C.), and Department of Medicine, Division of Pulmonary, Allergy and Critical Care (H.A.A.), Duke University Medical Center, Durham, NC
1 shared publication
Latest Publications
- 18 September 2025
- Published by Wiley in Clinical Transplantation
- Vol. 39 (9) , e70295
Passenger Lymphocyte Syndrome Presenting With Severe Refractory Thrombocytopenia After Transplantation: A Multi‐Recipient Case Series
Passenger lymphocyte syndrome (PLS) is an immune‐mediated complication that can occur following solid organ transplantation, resulting from the transfer of donor‐derived lymphocytes that produce alloantibodies targeting recipient antigens. We report a case series of PLS presenting as severe refractory thrombocytopenia in multiple recipients of solid organ transplantation from a single donor.
- 18 September 2025
- Published by Wiley in Clinical Transplantation
- Vol. 39 (9) , e70295
Passenger Lymphocyte Syndrome Presenting With Severe Refractory Thrombocytopenia After Transplantation: A Multi‐Recipient Case Series
Passenger lymphocyte syndrome (PLS) is an immune‐mediated complication that can occur following solid organ transplantation, resulting from the transfer of donor‐derived lymphocytes that produce alloantibodies targeting recipient antigens. We report a case series of PLS presenting as severe refractory thrombocytopenia in multiple recipients of solid organ transplantation from a single donor.
- Open Access
- 21 May 2025
- Published by Frontiers Media SA in Frontiers in Transplantation
- Vol. 4, 1583919
Long-term outcomes of a case-control lung transplant cohort after SARS-CoV-2 infection
Background: Respiratory viruses can impact the allograft function in lung transplant recipients, but it is unknown if this occurs with SARS-CoV-2 infection. We studied the long-term outcomes of lung transplant recipients infected with SARS-CoV-2.Methods: This single-center retrospective study compared lung transplant recipients with SARS-CoV-2 between June 2020 and April 2021 with a matched control group. Within the SARS-CoV-2 cohort, univariable associations between clinical factors and outcomes were tested. Changes in pulmonary function tests were analyzed. Primary endpoints included acute cellular rejection and all-cause mortality within 12 months.Results: Fifty-three lung transplant recipients were infected with SARS-CoV-2. The median age was 64 years. 29 (54.7%) were managed outpatient, and 24 (45.3%) required hospitalization, with 13 intensive care unit admissions. All-cause mortality was 24.5%. Within the SARS-CoV-2 cohort, older age was significantly associated with all-cause mortality (p-value 0.017) as was ICU admission (p = 0.009) and an A1C > 6.5 (p = 0.033). The mean change in FEV1 was −1.1% at 3 months with minimal change at 6 and 12 months (−2.6% and −1% respectively), all compared to baseline. Acute cellular rejection was identified in 13.7% of the SARS-CoV-2 cohort compared to 11.8% in the matched control group; it was not significantly associated with the infection status (p = 0.706). However, all-cause mortality was significantly associated with infection status (p = 0.019).Conclusion: Long-term outcomes of SARS-CoV-2 in lung transplant recipients are widely variable. Within the SARS-CoV-2 cohort, all-cause mortality was 24.5%, and older age was significantly associated with mortality. We did not observe significant declines in FEV1 in this group.
- 21 May 2025
- Published by Frontiers Media SA in Frontiers in Transplantation
- Vol. 4, 1583919
Open AccessLong-term outcomes of a case-control lung transplant cohort after SARS-CoV-2 infection
Background: Respiratory viruses can impact the allograft function in lung transplant recipients, but it is unknown if this occurs with SARS-CoV-2 infection. We studied the long-term outcomes of lung transplant recipients infected with SARS-CoV-2.Methods: This single-center retrospective study compared lung transplant recipients with SARS-CoV-2 between June 2020 and April 2021 with a matched control group. Within the SARS-CoV-2 cohort, univariable associations between clinical factors and outcomes were tested. Changes in pulmonary function tests were analyzed. Primary endpoints included acute cellular rejection and all-cause mortality within 12 months.Results: Fifty-three lung transplant recipients were infected with SARS-CoV-2. The median age was 64 years. 29 (54.7%) were managed outpatient, and 24 (45.3%) required hospitalization, with 13 intensive care unit admissions. All-cause mortality was 24.5%. Within the SARS-CoV-2 cohort, older age was significantly associated with all-cause mortality (p-value 0.017) as was ICU admission (p = 0.009) and an A1C > 6.5 (p = 0.033). The mean change in FEV1 was −1.1% at 3 months with minimal change at 6 and 12 months (−2.6% and −1% respectively), all compared to baseline. Acute cellular rejection was identified in 13.7% of the SARS-CoV-2 cohort compared to 11.8% in the matched control group; it was not significantly associated with the infection status (p = 0.706). However, all-cause mortality was significantly associated with infection status (p = 0.019).Conclusion: Long-term outcomes of SARS-CoV-2 in lung transplant recipients are widely variable. Within the SARS-CoV-2 cohort, all-cause mortality was 24.5%, and older age was significantly associated with mortality. We did not observe significant declines in FEV1 in this group.
- 10 January 2024
- Published by Elsevier in Transplantation Proceedings
- Vol. 56 (1) , 153-160
Inadequate (Ax) Transbronchial Lung Transplant Biopsies—Scope and the Potential Contributing Factors
- 10 January 2024
- Published by Elsevier in Transplantation Proceedings
- Vol. 56 (1) , 153-160
Inadequate (Ax) Transbronchial Lung Transplant Biopsies—Scope and the Potential Contributing Factors
- Open Access
- 21 November 2023
- Published by LIDSEN Publishing Inc in OBM Transplantation
- Vol. 07 (04) , 1-32
Acute Rejection of the Lung Allograft: Phenotypes and Management
Treatment options for end stage lung diseases are limited to stabilizing lung failure, decreasing disease progression, and symptom management, but significant reversal of lost lung function is often not possible. For well selected patients, lung transplantation may be a viable option to improve both longevity and quality of life. Though outcomes for lung transplant recipients have improved over several decades, long term survival still lags behind that of other solid organ transplant recipients. Longevity after lung transplantation is limited by chronic lung allograft dysfunction. Numerous insults to the allograft contribute to chronic rejection, alloimmune injuries including acute T-cell mediated and antibody mediated rejection are chief among them. Therefore, monitoring for and management of acute cellular and antibody mediated rejection are of paramount importance to those caring for lung transplant recipients. We provide an up to date and comprehensive review of acute rejection affecting lung allografts and attempt to highlight pathophysiology, risk factors, clinical presentation, rejection phenotypes, management strategies, as well as related from of acute allograft injury.
- 21 November 2023
- Published by LIDSEN Publishing Inc in OBM Transplantation
- Vol. 07 (04) , 1-32
Open AccessAcute Rejection of the Lung Allograft: Phenotypes and Management
Treatment options for end stage lung diseases are limited to stabilizing lung failure, decreasing disease progression, and symptom management, but significant reversal of lost lung function is often not possible. For well selected patients, lung transplantation may be a viable option to improve both longevity and quality of life. Though outcomes for lung transplant recipients have improved over several decades, long term survival still lags behind that of other solid organ transplant recipients. Longevity after lung transplantation is limited by chronic lung allograft dysfunction. Numerous insults to the allograft contribute to chronic rejection, alloimmune injuries including acute T-cell mediated and antibody mediated rejection are chief among them. Therefore, monitoring for and management of acute cellular and antibody mediated rejection are of paramount importance to those caring for lung transplant recipients. We provide an up to date and comprehensive review of acute rejection affecting lung allografts and attempt to highlight pathophysiology, risk factors, clinical presentation, rejection phenotypes, management strategies, as well as related from of acute allograft injury.
- 29 April 2023
- Published by Elsevier in Journal of Cardiothoracic and Vascular Anesthesia
- Vol. 37 (9) , 1609-1617
Development of New Donor-Specific and Human Leukocyte Antigen Antibodies After Transfusion in Adult Lung Transplantation
- 29 April 2023
- Published by Elsevier in Journal of Cardiothoracic and Vascular Anesthesia
- Vol. 37 (9) , 1609-1617
Development of New Donor-Specific and Human Leukocyte Antigen Antibodies After Transfusion in Adult Lung Transplantation
- 1 August 2021
- Published by Radiological Society of North America (RSNA) in Radiology: Cardiothoracic Imaging
- Vol. 3 (4) , e190252
Complications of Lung Transplantation: Update on Imaging Manifestations and Management
Considering the steadily increasing rate of lung transplantation surgeries, it is crucial for radiologists to understand imaging manifestations of common complications of this surgery to contribute... As lung transplantation has become the most effective definitive treatment option for end-stage chronic respiratory diseases, yearly rates of this surgery have been steadily increasing. Despite imp...
- 1 August 2021
- Published by Radiological Society of North America (RSNA) in Radiology: Cardiothoracic Imaging
- Vol. 3 (4) , e190252
Complications of Lung Transplantation: Update on Imaging Manifestations and Management
Considering the steadily increasing rate of lung transplantation surgeries, it is crucial for radiologists to understand imaging manifestations of common complications of this surgery to contribute... As lung transplantation has become the most effective definitive treatment option for end-stage chronic respiratory diseases, yearly rates of this surgery have been steadily increasing. Despite imp...
- 15 September 2020
- Published by Wolters Kluwer Health in Transplantation
- Vol. 105 (7) , 1403-1404
Imaging in Lung Transplantation: So Near and Yet So Far
An abstract is unavailable. This article is available as a PDF only.
- 15 September 2020
- Published by Wolters Kluwer Health in Transplantation
- Vol. 105 (7) , 1403-1404
Imaging in Lung Transplantation: So Near and Yet So Far
An abstract is unavailable. This article is available as a PDF only.